Black Agenda Report
Black Agenda Report
News, commentary and analysis from the black left.

  • Home
  • Africa
  • African America
  • Education
  • Environment
  • International
  • Media and Culture
  • Political Economy
  • Radio
  • US Politics
  • War and Empire

Obamacare A Bonanza For Drug Companies, A Pain For the Public
Glen Ford, BAR executive editor
18 Nov 2009
🖨️ Print Article
expensive drugs
A Black Agenda Radio commentary by Glen Ford
Click the flash player to listen to or the mic to download an audio in MP3 format.

Why are the drug barons planning a $150 million ad campaign boosting Obama's health care scheme? They've got $21 billion worth of reasons – bonus earnings from record price hikes while wheeling and dealing with the White House. Everything the president touches turns to cash – for the corporate sector.
 
Obamacare A Bonanza For Drug Companies, A Pain For the Public
A Black Agenda Radio commentary by Glen Ford
“Obama's dealmaking in the White House is nothing less than collusion with the cartel.”
President Obama is very good at talking “the language of the deal.” He made a deal with the the drug cartel this summer, ostensibly to keep drug prices down to reduce the overall cost of health care. The drug companies promised they would cut the prices they planned to charge by about $8 billion a year for the next ten years. Now an analysis for AARP shows the drug profiteers have actually raised prices by more than $10 billion in the last year, an increase of more than 9 percent and the biggest price hike in 17 years.
Good lookin' out out, Obama. Or should I say, Good job of selling out, Mr. President. The drug industry is so happy with the deal it cut with the White House, it's launching a $150 million advertising campaign to boost ObamaCare – a cheap price to pay for yet another Obama bailout of the ruling class, this time for Big Pharma.
At the same time that the industry was pushing up drug prices by 9.3 percent, the price of generic drugs declined by about 9 percent. That means the drug cartel, under cover of Obama's deal, transformed a downward trend in pharmaceutical prices into the biggest price surge since 1992.
And what else is the drug monopoly getting from the dealmaker in the White House? Thirty million new customers, served up on a platter under the banner of health care reform. This is bait-and-switch with a vengeance. When Obama is the dealmaker, “reform” translates into instant, unprecedented profits for the corporate sector. Under this administration, the words “reform” and “bailout” are virtually synonymous.
“The drug cartel, under cover of Obama's deal, transformed a downward trend in pharmaceutical prices into the biggest price surge since 1992.”
The House version of health care reform, passed on November 7th, calls for $14 billion a year in savings on drugs, but most of those savings have already been gutted by the drug industry. So what did the Democrats accomplish by deferring to the deal struck by the White House? They have made themselves look ridiculous, irrelevant.
The drug industry pulled the same trick back in 2006, when Congress expanded the Medicare subsidized drug program by tens of millions of older people. Back then, Big Pharma seized the opportunity to push prices through the roof. Now they've done it again.
If Barack Obama is not a pro-big business president, then who is? He has guaranteed the drug barons tens of millions of captive customers, shielded the industry from pesky progressives in Congress by cutting a side deal at the White House, and then allowed the corporations to reap a $21 billion boondoggle based entirely on artificially inflated prices.
Why do Americans pay so much more for pharmaceuticals than anyone else on the planet? Because the drug industry is a cartel that sets prices as it sees fit. Barack Obama's dealmaking in the White House is nothing less than collusion with the cartel.
No one questions Barack Obama's intelligence. He is clearly a brilliant man. Therefore, one can only conclude that he is part of the con game. Obama is dealing from the bottom of the deck, passing all the good cards to his corporate partners. And the people get fleeced every time.
For Black Agenda Radio, I'm Glen Ford. On the web, go to www.BlackAgendaReport.com.

BAR executive editor Glen Ford can be contacted at Glen.Ford@BlackAgendaReport.com. 

Do you need and appreciate Black Agenda Report articles? Please click on the DONATE icon, and help us out, if you can.


More Stories


  • On George Jackson and Julian Assange
    Patrick D. Anderson
    On George Jackson and Julian Assange
    13 May 2020
    Both see the United States as the Empire, and they agree that it must be opposed.
  • Can We Simultaneously Oppose Bayer/Monsanto’s Biotechnology and Support Cuba’s Interferon Alpha 2B?
    Don Fitz
    Can We Simultaneously Oppose Bayer/Monsanto’s Biotechnology and Support Cuba’s Interferon Alpha 2B?
    13 May 2020
    It is necessary to compare the use of biotechnology by food corporations with that of Cuba to decide if they are the same or fundamentally different.
  • Chicago Mayor Lightfoot’s Coronavirus Threats and Government Incapacity to Handle a Pandemic
    Stansfield Smith
    Chicago Mayor Lightfoot’s Coronavirus Threats and Government Incapacity to Handle a Pandemic
    13 May 2020
    The city’s Black mayor threatened Black house partyers with arrest, but ignored 500 un-masked white people protesting the Covid-19 lock-down.
  • Black Agenda Radio for Week of May 11, 2020
    Black Agenda Radio with Margaret Kimberley and Glen Ford
    Black Agenda Radio for Week of May 11, 2020
    11 May 2020
    Biden’s “Lift Every Voice” Proposal Appeals to Black Misleaders
  • “Scent of Africa” Marketed to “Afropolitans”
    Black Agenda Radio with Margaret Kimberley and Glen Ford
    “Scent of Africa” Marketed to “Afropolitans”
    11 May 2020
    Fifty years after most African nations won nominal independence, ad agencies are marketing upscale products like the perfume “Scent of Africa” to so-called “Afropolitans,” a cohort defined by 
  • Load More
Subscribe
connect with us
about us
contact us